A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

BACKGROUND: Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of patients with HER2-overexpressing advanced EGJ or GC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Valeria, Zecchetto, Camilla, Simionato, Francesca, Cavaliere, Alessandro, Casalino, Simona, Pavarana, Michele, Giacopuzzi, Simone, Bencivenga, Maria, Tomezzoli, Anna, Santoro, Raffaela, Fedele, Vita, Contarelli, Serena, Rossi, Irene, Giacomazzi, Serena, Pasquato, Martina, Piazzola, Cristiana, Milleri, Stefano, de Manzoni, Giovanni, Melisi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346700/
https://www.ncbi.nlm.nih.gov/pubmed/32684989
http://dx.doi.org/10.1177/1758835920937889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346700/
https://www.ncbi.nlm.nih.gov/pubmed/32684989
http://dx.doi.org/10.1177/1758835920937889

Ejemplares similares